Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Background Prior studies indicated a decrease in the incidences of aneurysmal subarachnoid haemorrhage (aSAH) during the early stages of the COVID-19 pandemic. We evaluated differences in the incidence, severity of aSAH presentation, and ruptured aneurysm treatment modality during the first year of the COVID-19 pandemic compared with the preceding year. Methods We conducted a cross-sectional study including 49 countries and 187 centres. We recorded volumes for COVID-19 hospitalisations, aSAH hospitalisations, Hunt-Hess grade, coiling, clipping and aSAH in-hospital mortality. Diagnoses were identified by International Classification of Diseases, 10th Revision, codes or stroke databases from January 2019 to May 2021. Results Over the study period, there were 16 247 aSAH admissions, 344 491 COVID-19 admissions, 8300 ruptured aneurysm coiling and 4240 ruptured aneurysm clipping procedures. Declines were observed in aSAH admissions (-6.4% (95% CI-7.0% to-5.8%), p=0.0001) during the first year of the pandemic compared with the prior year, most pronounced in high-volume SAH and high-volume COVID-19 hospitals. There was a trend towards a decline in mild and moderate presentations of subarachnoid haemorrhage (SAH) (mild:-5% (95% CI-5.9% to-4.3%), p=0.06; moderate:-8.3% (95% CI-10.2% to-6.7%), p=0.06) but no difference in higher SAH severity. The ruptured aneurysm clipping rate remained unchanged (30.7% vs 31.2%, p=0.58), whereas ruptured aneurysm coiling increased (53.97% vs 56.5%, p=0.009). There was no difference in aSAH in-hospital mortality rate (19.1% vs 20.1%, p=0.12). Conclusion During the first year of the pandemic, there was a decrease in aSAH admissions volume, driven by a decrease in mild to moderate presentation of aSAH. There was an increase in the ruptured aneurysm coiling rate but neither change in the ruptured aneurysm clipping rate nor change in aSAH in-hospital mortality. Trial registration number NCT04934020.
Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up
Nguyen T. N.;Qureshi M. M.;Klein P.;Yamagami H.;Mikulik R.;Etminan N.;Abdalkader M.;Mansour O. Y.;Czlonkowska A.;Lo H.;Sathya A.;Demeestere J.;Tsivgoulis G.;Sakai N.;Sedova P.;Kristoffersen E. S.;Mohammaden M.;Lereis V. P.;Scollo S. D.;Ma A.;Rahman A.;Bonnet T.;Cortier J.;Raedt S. D.;Lemmens R.;Ligot N.;Hidalgo R. C. T.;Cuervo D. L. M.;De Oliveira Neves L.;Rezende M. T. S.;Santiago I. B.;Sirakov A.;Sirakov S.;Cora E. A.;Kelly M. E.;Lavoie P.;Peeling L.;Pikula A.;Rivera R.;Chen H. -S.;Chen Y.;Fang H.;Bedekovic M. R.;Budincevic H.;Strossmayer J. J.;Cabal M.;Hrabanovska E.;Jurak L.;Kadlckova J.;Karpowicz I.;Klecka L.;Kovar M.;Neumann J.;Palouskova H.;Reiser M.;Rekova P.;Skorna M.;Sramek M.;Vitkova E.;Zakova L.;Sobh K.;Alpay K.;Rautio R.;Strbian D.;Gentric J. -C.;Magro E.;Naggara O.;Reiner P.;Abdulazim A.;Bohmann F. O.;Boskamp S.;Gerber J. C.;Kaiser D. P. O.;Kestner R. I.;Mbroh J.;Neyazi M.;Rosenkranz M.;Poli S.;Thomalla G.;Karapanayiotides T.;Kargiotis O.;Koutroulou I.;Palaiodimou L.;Guerra J. D. B.;Huded V.;Nagendra S.;Prajapati C.;Krishna A.;Sani A. F.;Ghoreishi A.;Ilkhchi R. B.;Jalili J.;Sabetay S. I.;Raya T. A.;Acampa M.;Longoni M.;Bigliani C. R.;Castellan L.;Ornello R.;Renieri L.;Romoli M.;Sacco S.;Sangalli D.;Vigano M.;Zini A.;Tokimura H.;Sonoda K.;Todo K.;Fukuda H.;Fujita K.;Sakaguchi M.;Uno M.;Kan I.;Kosuke M.;Kono R.;Kimura N.;Yamamoto N.;Yamamoto R.;Doijiri R.;Shindo S.;Ohara N.;Imamura H.;Ogawa T.;Uwatoko T.;Kanamaru T.;Fujinaka T.;Takenobu Y.;Toyoda K.;Matsumaru Y.;Yazawa Y.;Sugiura Y.;Baek J. -H.;Kwon Y. S.;Lee Y. H.;Seo K. -D.;Sohn S. -I.;Chan Y. C.;Wan Zaidi W. A.;Barrientos-Prieto J.;Gongora-Rivera F.;Martinez-Marino M.;Calderon-Vallejo A.;Groppa S.;Pavel L.;Coutinho J. M.;Dippel D.;Rinkel L.;Van Dam-Nolen D. H. K.;Nwazor E. O.;Sunmonu T. A.;Al Hashmi A. M.;Ahmad S.;Rashid U.;Rodriguez-Kadota L.;Vences M. A.;Yalung P. M.;Dy J. S. H.;Brola W.;Debiec A.;Dorobek M.;Karlinski M. A.;Labuz-Roszak B. M.;Lasek-Bal A.;Sienkiewicz-Jarosz H.;Staszewski J.;Sobolewski P.;Wiacek M.;Zielinska-Turek J.;Araujo A. P.;Fonseca L.;Silva M. L.;Castro P.;Rocha M.;Falup-Pecurariu R. C.;Venketasubramanian N.;Krastev G.;Mako M.;Ayo-Martin O.;Blasco J.;Cruz-Culebras A.;Hernandez-Fernandez F.;Fernandez C. R.;Lopez J. E.;Rodriguez A.;Bolognese M.;Karwacki G. M.;Keller E.;MacHi P.;Bernava G.;Boonyakarnkul S.;Churojana A.;Hammami N.;Bajrami A.;Senadim S.;Hussain S. I.;John S.;Dow G.;Krishnan K.;Lenthall R.;Wong K.;Zhang L.;Altschul D.;Asif K. S.;Aziz-Sultan M. A.;Bach I.;Bahiru Z.;Below K.;Biller J.;Cervantes-Arslanian A. M.;Chaudhry S. A.;Chebl A.;Chen M.;Colasurdo M.;Czap A.;Dasenbrock H.;De Havenon A. H.;Dharmadhikari S.;Dmytriw A. A.;Eskey C. J.;Etherton M.;Ezepue C.;Fink L.;Gasimova U.;Goyal N.;Grimmett K. B.;Hakemi M.;Hester T.;Inoa V.;Kan P. T.;Kasper E. M.;Khandelwal P.;Khatri R.;Khawaja A. M.;Khoury N. N.;Kim B. S.;Kolikonda M.;Kuhn A. L.;Linares G.;Linfante I.;Loochtan A. I.;Lukovits T. G.;Male S. S.;Maali L.;Masoud H. E.;Galecio-Castillo E. M.;Min J.;Mohamed G. A.;Nalleballe K.;Ortega-Gutierrez S.;Puri A. S.;Radaideh Y.;Rahangdale R. H.;Ramakrishnan P.;Reddy A. B.;Ruland S.;Omran S. S.;Sheth S. A.;Siegler J. E.;Starosciak A. K.;Tarlov N. E.;Taylor R. A.;Tsai J.;Wang M. J.;Wong K. -H.;Zaidat O. O.;Le H. V.;Pham T. N.;Phan H. T.;Ton M. D.;Tran A. D.;Sirakova K.;Mohlenbruch M. A.;Nagel S.;Raymond J.;Nogueira R. G.
2022-01-01
Abstract
Background Prior studies indicated a decrease in the incidences of aneurysmal subarachnoid haemorrhage (aSAH) during the early stages of the COVID-19 pandemic. We evaluated differences in the incidence, severity of aSAH presentation, and ruptured aneurysm treatment modality during the first year of the COVID-19 pandemic compared with the preceding year. Methods We conducted a cross-sectional study including 49 countries and 187 centres. We recorded volumes for COVID-19 hospitalisations, aSAH hospitalisations, Hunt-Hess grade, coiling, clipping and aSAH in-hospital mortality. Diagnoses were identified by International Classification of Diseases, 10th Revision, codes or stroke databases from January 2019 to May 2021. Results Over the study period, there were 16 247 aSAH admissions, 344 491 COVID-19 admissions, 8300 ruptured aneurysm coiling and 4240 ruptured aneurysm clipping procedures. Declines were observed in aSAH admissions (-6.4% (95% CI-7.0% to-5.8%), p=0.0001) during the first year of the pandemic compared with the prior year, most pronounced in high-volume SAH and high-volume COVID-19 hospitals. There was a trend towards a decline in mild and moderate presentations of subarachnoid haemorrhage (SAH) (mild:-5% (95% CI-5.9% to-4.3%), p=0.06; moderate:-8.3% (95% CI-10.2% to-6.7%), p=0.06) but no difference in higher SAH severity. The ruptured aneurysm clipping rate remained unchanged (30.7% vs 31.2%, p=0.58), whereas ruptured aneurysm coiling increased (53.97% vs 56.5%, p=0.009). There was no difference in aSAH in-hospital mortality rate (19.1% vs 20.1%, p=0.12). Conclusion During the first year of the pandemic, there was a decrease in aSAH admissions volume, driven by a decrease in mild to moderate presentation of aSAH. There was an increase in the ruptured aneurysm coiling rate but neither change in the ruptured aneurysm clipping rate nor change in aSAH in-hospital mortality. Trial registration number NCT04934020.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/840802
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Citazioni
ND
21
16
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
